Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on HEXO (HEXO) and Knight Therapeutics (KHTRF).
HEXO (HEXO)
Canaccord Genuity analyst Matt Bottomley maintained a Hold rating on HEXO yesterday and set a price target of C$1.30. The company’s shares closed last Monday at $0.79, close to its 52-week low of $0.35.
According to TipRanks.com, Bottomley is a 1-star analyst with an average return of -2.2% and a 40.5% success rate. Bottomley covers the Healthcare sector, focusing on stocks such as Harvest Health & Recreation, Green Thumb Industries, and MedMen Enterprises.
HEXO has an analyst consensus of Moderate Sell, with a price target consensus of $1.19, which is a 28.0% upside from current levels. In a report issued on March 16, MKM Partners also maintained a Hold rating on the stock with a C$1.00 price target.
See today’s analyst top recommended stocks >>
Knight Therapeutics (KHTRF)
Canaccord Genuity analyst Tania Gonsalves maintained a Buy rating on Knight Therapeutics today and set a price target of C$9.75. The company’s shares closed last Monday at $4.25.
According to TipRanks.com, Gonsalves is ranked #5299 out of 6216 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $7.24 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
